{
    "clinical_study": {
        "@rank": "45095", 
        "acronym": "C-WORTHy", 
        "arm_group": [
            {
                "arm_group_label": "A: TN/N-C MK-5172+MK-8742 20 mg+RBV", 
                "arm_group_type": "Experimental", 
                "description": "GT1a and GT1b participants receive MK-5172 100 mg tablet orally QD for 12 weeks, MK-8742 20 mg capsule and Placebo capsule orally QD for 12 weeks, RBV capsules orally BID for 24 weeks at a total daily dose from 800 to 1400 mg based on participant weight"
            }, 
            {
                "arm_group_label": "A: TN/N-C MK-5172+MK-8742 50 mg+RBV", 
                "arm_group_type": "Experimental", 
                "description": "GT1a and GT1b participants receive MK-5172 100 mg tablet orally QD for 12 weeks, MK-8742 50 mg capsule and Placebo capsule orally QD for 12 weeks, RBV capsules orally BID for 24 weeks at a total daily dose from 800 to 1400 mg based on participant weight"
            }, 
            {
                "arm_group_label": "A: TN/N-C MK-5172+MK-8742 50 mg", 
                "arm_group_type": "Experimental", 
                "description": "GT1b only participants receive MK-5172 100 mg tablet orally QD for 12 weeks, MK-8742 50 mg capsule orally QD for 12 weeks"
            }, 
            {
                "arm_group_label": "B: TN/N-C MK-5172+MK-8742+RBV 8 wk", 
                "arm_group_type": "Experimental", 
                "description": "GT1a only participants receive MK-5172 100 mg tablet orally QD for 8 weeks, MK-8742 50 mg capsule orally QD for 8 weeks, RBV capsules orally BID for 8 weeks at a total daily dose from 800 to 1400 mg based on participant weight"
            }, 
            {
                "arm_group_label": "B: TN/N-C MK-5172+MK-8742+RBV 12 wk", 
                "arm_group_type": "Experimental", 
                "description": "GT1a/non-a participants receive MK-5172 100 mg tablet orally QD for 12 weeks, MK-8742 50 mg capsule orally QD for 12 weeks, RBV capsules orally BID for 12 weeks at a total daily dose from 800 to 1400 mg based on participant weight"
            }, 
            {
                "arm_group_label": "B: TN/N-C MK-5172+MK-8742 12 wk", 
                "arm_group_type": "Experimental", 
                "description": "GT1a only participants receive MK-5172 100 mg tablet orally QD for 12 weeks, MK-8742 50 mg capsule orally QD for 12 weeks"
            }, 
            {
                "arm_group_label": "B: TN/C MK-5172+MK-8742+RBV 12 wk", 
                "arm_group_type": "Experimental", 
                "description": "GT1a/non-a participants receive MK-5172 100 mg tablet orally QD for 12 weeks, MK-8742 50 mg capsule orally QD for 12 weeks, RBV capsules orally BID for 12 weeks at a total daily dose from 800 to 1400 mg based on participant"
            }, 
            {
                "arm_group_label": "B: TN/C MK-5172+MK-8742 12 wk", 
                "arm_group_type": "Experimental", 
                "description": "GT1a/non-a participants receive MK-5172 100 mg tablet orally QD for 12 weeks, MK-8742 50 mg capsule orally QD for 12 weeks"
            }, 
            {
                "arm_group_label": "B: TN/C MK-5172+MK-8742+RBV 18 wk", 
                "arm_group_type": "Experimental", 
                "description": "GT1a/non-a participants receive MK-5172 100 mg tablet orally QD for 18 weeks, MK-8742 50 mg capsule orally QD for 18 weeks, RBV capsules orally BID for 18 weeks at a total daily dose from 800 to 1400 mg based on participant weight"
            }, 
            {
                "arm_group_label": "B: TN/C MK-5172+MK-8742 18 wk", 
                "arm_group_type": "Experimental", 
                "description": "GT1a/non-a participants receive MK-5172 100 mg tablet orally QD for 18 weeks, MK-8742 50 mg capsule orally QD for 18 weeks"
            }, 
            {
                "arm_group_label": "B: NR/C/N-C MK-5172+MK-8742+RBV 12 wk", 
                "arm_group_type": "Experimental", 
                "description": "GT1a/non-a participants receive MK-5172 100 mg tablet orally QD for 12 weeks, MK-8742 50 mg capsule orally QD for 12 weeks, RBV capsules orally BID for 12 weeks at a total daily dose from 800 to 1400 mg based on participant weight"
            }, 
            {
                "arm_group_label": "B: NR/C/N-C MK-5172+MK-8742 12 wk", 
                "arm_group_type": "Experimental", 
                "description": "GT1a/non-a participants receive MK-5172 100 mg tablet orally QD for 12 weeks, MK-8742 50 mg capsule orally QD for 12 weeks"
            }, 
            {
                "arm_group_label": "B: NR/C/N-C MK-5172+MK-8742+RBV 18 wk", 
                "arm_group_type": "Experimental", 
                "description": "GT1a/non-a participants receive MK-5172 100 mg tablet orally QD for 18 weeks, MK-8742 50 mg capsule orally QD for 18 weeks, RBV capsules orally BID for 18 weeks at a total daily dose from 800 to 1400 mg based on participant weight"
            }, 
            {
                "arm_group_label": "B: NR/C/N-C MK-5172+MK-8742 18 wk", 
                "arm_group_type": "Experimental", 
                "description": "GT1a/non-a participants receive MK-5172 100 mg tablet orally QD for 18 weeks, MK-8742 50 mg capsule orally QD for 18 weeks"
            }, 
            {
                "arm_group_label": "B: TN/N-C/HIV MK-5172+MK-8742+RBV 12 wk", 
                "arm_group_type": "Experimental", 
                "description": "GT1a/non-a participants receive MK-5172 100 mg tablet orally QD for 12 weeks, MK-8742 50 mg capsule orally QD for 12 weeks, RBV capsules orally BID for 12 weeks at a total daily dose from 800 to 1400 mg based on participant weight"
            }, 
            {
                "arm_group_label": "B: TN/N-C/HIV MK-5172+MK-8742 12 wk", 
                "arm_group_type": "Experimental", 
                "description": "GT1a/non-a participants receive MK-5172 100 mg tablet orally QD for 12 weeks, MK-8742 50 mg capsule orally QD for 12 weeks"
            }, 
            {
                "arm_group_label": "C: TN/N-C MK-5172+MK-8742+RBV 8 wk", 
                "arm_group_type": "Experimental", 
                "description": "GT1b participants receive MK-5172 100 mg tablet orally QD for 8 weeks, MK-8742 50 mg capsule orally QD for 8 weeks, and RBV capsules orally BID for 8 weeks at a total daily dose from 800 to 1400 mg based on participant weight."
            }, 
            {
                "arm_group_label": "C: TN/N-C MK-5172+MK-8742 8wk", 
                "arm_group_type": "Experimental", 
                "description": "GT1b participants receive MK-5172 100 mg tablet orally QD for 8 weeks and MK-8742 50 mg capsule orally QD for 8 weeks"
            }, 
            {
                "arm_group_label": "D: TN/N-C MK-5172+MK-8742+RBV 12 wk", 
                "arm_group_type": "Experimental", 
                "description": "GT3 participants receive MK-5172 100 mg tablet orally QD for 12 weeks, MK-8742 50 mg capsule orally QD for 12 weeks, and RBV capsules orally BID for 12 weeks at a total daily dose from 800 to 1400 mg based on participant weight"
            }, 
            {
                "arm_group_label": "D: TN/N-C MK-5172+MK-8742+RBV 18 wk", 
                "arm_group_type": "Experimental", 
                "description": "GT3 participants receive MK-5172 100 mg tablet orally QD for 18 weeks, MK-8742 50 mg capsule orally QD for 18 weeks, and RBV capsules orally BID for 18 weeks at a total daily dose from 800 to 1400 mg based on participant weight"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a study of the safety and efficacy of MK-5172 in combination with MK-8742 \u00b1\n      ribavirin (RBV).  The primary efficacy endpoint will be Sustained Virologic Response 12\n      weeks after the end of all study therapy (SVR12) in each of the treatment arms."
        }, 
        "brief_title": "A Study of the Combination Regimen MK-5172 and MK-8742 \u00b1 Ribavirin in Participants With Chronic Hepatitis C (MK-5172-035)", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis C", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "Part A is being done in treatment-na\u00efve (TN), genotype 1 (GT1), interferon eligible,\n      non-cirrhotic (N-C) participants with chronic hepatitis C (CHC). Participants will be\n      assigned randomly to 1 of 2 treatment arms in which they will receive MK-5172 100 mg once\n      daily (QD) + MK-8742 20 mg or 50 mg QD and twice daily (BID) RBV, or to a treatment arm in\n      which they will receive MK-5172 100 mg QD + MK-8742 50 mg QD without RBV. Treatment will\n      last 12 weeks.\n\n      In Part B, participants with hepatitis C virus (HCV) GT1 and HCV ribonucleic acid (RNA)\n      levels of \u226510,000 IU/mL will be randomly assigned to a study arm, based on absence or\n      presence of cirrhosis (C), whether they are TN or had poor response to previous antiviral\n      therapy (null responders [NR]), or whether co-infected with human immunodeficiency virus\n      (HIV); these participants will receive open-label MK-5172 (100 mg) in combination with\n      MK-8742 (50 mg) \u00b1 RBV. Treatment will last 8 to 18 weeks dependent on arm assignment.\n\n      In Part C, TN, N-C participants with HCV GT1b and HCV RNA levels of \u226510,000 IU/mL will be\n      randomly assigned to receive open-label MK-5172 (100 mg) in combination with MK-8742 (50 mg)\n      \u00b1 RBV. Treatment will last 8 weeks.\n\n      In Part D, TN N-C participants with HCV GT3 and  HCV RNA levels of \u226510,000 IU/mL will be\n      randomly assigned to receive open-label MK-5172 (100 mg) in combination with MK-8742 (50 mg)\n      + RBV for 12 or 18 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n        All participants - CHC genotype 1 (GT1) virus infection (Parts A, B, and C) or GT3 virus\n        infection (Part D) - Female participants of childbearing potential or male participant\n        with female partners of childbearing potential, must use two acceptable methods of birth\n        control from \u22652 weeks prior to Day 1 until \u22656 months after last dose of study drug, or\n        longer if dictated by local regulations\n\n        Part A - Absence (no medical history or physical findings) of ascites, bleeding esophageal\n        varices, hepatic encephalopathy, or other signs or symptoms of advanced liver disease, or\n        cirrhosis - No evidence of advanced fibrosis, cirrhosis and/or hepatocellular carcinoma by\n        biopsy or noninvasive testing (FibroScan and/or FibroTest)\n\n        Parts B, C, and D - Treatment na\u00efve with or without cirrhosis, or - Prior treatment\n        failure to Peg-IFN/Ribavirin with or without cirrhosis, or - Co-infected with human\n        immunodeficiency virus (HIV) without cirrhosis -Absence (no medical history or physical\n        findings) of ascites, bleeding esophageal varices, hepatic encephalopathy, or other signs\n        or symptoms of advanced liver disease - Liver disease staging assessment by liver biopsy\n        or noninvasive testing (FibroScan and/or FibroTest)\n\n        Exclusion criteria:\n\n        All participants - Non-GT1 HCV infection (Part A, Part B, and Part C) or a non-GT3 HCV\n        infection (Part D) including a mixed GT infection (with a non-GT1 [Part A, Part B, and\n        Part C] or non-GT3 [Part D]) or a non-typeable genotype - Evidence of hepatocellular\n        carcinoma (HCC) or is under evaluation for HCC - Currently participating or participated\n        in a study with an investigational compound within 30 days of signing informed consent and\n        is not willing to refrain from participating in another study - Diabetic and/or\n        hypertensive with clinically significant ocular examination findings - History of\n        depression associated with hospitalization for depression, electroconvulsive therapy, or\n        resulting in prolonged absence from work and/or significant disruption of daily functions\n        - Suicidal or homicidal ideations and/or attempt, or history of severe psychiatric\n        disorders - Clinical diagnosis of substance abuse - Current history of seizure disorder,\n        stroke, or transient ischemic attack - Immunologically mediated disease - Chronic\n        pulmonary disease - Clinically significant cardiac abnormalities/dysfunction - Active\n        clinical gout within the last year - Hemoglobinopathy or myelodysplastic syndromes -\n        History of organ transplants including hematopoietic stem cell transplants - Poor venous\n        access - Indwelling venous catheter - History of gastric surgery or malabsorption\n        disorders - Severe concurrent disease - Evidence of active or suspected malignancy, or a\n        history of malignancy, \u22645 years before - Pregnant, lactating, expecting to conceive or\n        donate eggs - Male participant with pregnant female partner - Member/family member of the\n        investigational study or sponsor staff directly involved with this study - Evidence or\n        history of chronic hepatitis not caused by HCV\n\n        Part A - Not treatment-na\u00efve - Documented to be HIV positive - Taking or planning to take\n        significant inducers or inhibitors of CYP3A4 substrates or herbal supplements 2 weeks\n        prior to start of study medications\n\n        Parts B, C, and D - Previously received any HCV direct-acting antivirals - Requiring, or\n        likely to require, chronic systemic administration of corticosteroids during the course of\n        the trial - For participants diagnosed with diabetes mellitus, documented HbA1c >8.5%"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "610", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 26, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01717326", 
            "org_study_id": "5172-035", 
            "secondary_id": "2012-003354-89"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "A: TN/N-C MK-5172+MK-8742 20 mg+RBV", 
                    "A: TN/N-C MK-5172+MK-8742 50 mg+RBV", 
                    "A: TN/N-C MK-5172+MK-8742 50 mg", 
                    "B: TN/N-C MK-5172+MK-8742+RBV 8 wk", 
                    "B: TN/N-C MK-5172+MK-8742+RBV 12 wk", 
                    "B: TN/N-C MK-5172+MK-8742 12 wk", 
                    "B: TN/C MK-5172+MK-8742+RBV 12 wk", 
                    "B: TN/C MK-5172+MK-8742 12 wk", 
                    "B: TN/C MK-5172+MK-8742+RBV 18 wk", 
                    "B: TN/C MK-5172+MK-8742 18 wk", 
                    "B: NR/C/N-C MK-5172+MK-8742+RBV 12 wk", 
                    "B: NR/C/N-C MK-5172+MK-8742 12 wk", 
                    "B: NR/C/N-C MK-5172+MK-8742+RBV 18 wk", 
                    "B: NR/C/N-C MK-5172+MK-8742 18 wk", 
                    "B: TN/N-C/HIV MK-5172+MK-8742+RBV 12 wk", 
                    "B: TN/N-C/HIV MK-5172+MK-8742 12 wk", 
                    "C: TN/N-C MK-5172+MK-8742+RBV 8 wk", 
                    "C: TN/N-C MK-5172+MK-8742 8wk", 
                    "D: TN/N-C MK-5172+MK-8742+RBV 12 wk", 
                    "D: TN/N-C MK-5172+MK-8742+RBV 18 wk"
                ], 
                "description": "100 mg tablet orally QD", 
                "intervention_name": "MK-5172", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "A: TN/N-C MK-5172+MK-8742 20 mg+RBV", 
                    "A: TN/N-C MK-5172+MK-8742 50 mg+RBV", 
                    "A: TN/N-C MK-5172+MK-8742 50 mg", 
                    "B: TN/N-C MK-5172+MK-8742+RBV 8 wk", 
                    "B: TN/N-C MK-5172+MK-8742+RBV 12 wk", 
                    "B: TN/N-C MK-5172+MK-8742 12 wk", 
                    "B: TN/C MK-5172+MK-8742+RBV 12 wk", 
                    "B: TN/C MK-5172+MK-8742 12 wk", 
                    "B: TN/C MK-5172+MK-8742+RBV 18 wk", 
                    "B: TN/C MK-5172+MK-8742 18 wk", 
                    "B: NR/C/N-C MK-5172+MK-8742+RBV 12 wk", 
                    "B: NR/C/N-C MK-5172+MK-8742 12 wk", 
                    "B: NR/C/N-C MK-5172+MK-8742+RBV 18 wk", 
                    "B: NR/C/N-C MK-5172+MK-8742 18 wk", 
                    "B: TN/N-C/HIV MK-5172+MK-8742+RBV 12 wk", 
                    "B: TN/N-C/HIV MK-5172+MK-8742 12 wk", 
                    "C: TN/N-C MK-5172+MK-8742+RBV 8 wk", 
                    "C: TN/N-C MK-5172+MK-8742 8wk", 
                    "D: TN/N-C MK-5172+MK-8742+RBV 12 wk", 
                    "D: TN/N-C MK-5172+MK-8742+RBV 18 wk"
                ], 
                "description": "Part A: 20 or 50 mg capsule orally QD Part B: 50 mg capsule orally QD", 
                "intervention_name": "MK-8742", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "A: TN/N-C MK-5172+MK-8742 20 mg+RBV", 
                    "A: TN/N-C MK-5172+MK-8742 50 mg+RBV"
                ], 
                "description": "Placebo to MK-8742 20 or 50 mg capsule, orally, once daily for 12 weeks to maintain blind (Part A only)", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "A: TN/N-C MK-5172+MK-8742 20 mg+RBV", 
                    "A: TN/N-C MK-5172+MK-8742 50 mg+RBV", 
                    "B: TN/N-C MK-5172+MK-8742+RBV 8 wk", 
                    "B: TN/N-C MK-5172+MK-8742+RBV 12 wk", 
                    "B: TN/C MK-5172+MK-8742+RBV 12 wk", 
                    "B: TN/C MK-5172+MK-8742+RBV 18 wk", 
                    "B: NR/C/N-C MK-5172+MK-8742+RBV 12 wk", 
                    "B: NR/C/N-C MK-5172+MK-8742+RBV 18 wk", 
                    "B: TN/N-C/HIV MK-5172+MK-8742+RBV 12 wk", 
                    "C: TN/N-C MK-5172+MK-8742+RBV 8 wk", 
                    "D: TN/N-C MK-5172+MK-8742+RBV 12 wk", 
                    "D: TN/N-C MK-5172+MK-8742+RBV 18 wk"
                ], 
                "description": "Oral capsules BID at a total daily dose from 800 to 1400 mg based on participant weight", 
                "intervention_name": "Ribavirin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Rebetol\u2122", 
                    "RBV"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ribavirin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 19, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Arlington", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "76012"
                }, 
                "name": "Call for Information (Investigational Site 0367)"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "20", 
        "official_title": "A Phase II Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen MK-5172 and MK-8742 \u00b1 Ribavirin (RBV) in Subjects With Chronic Hepatitis C Virus Infection", 
        "overall_contact": {
            "last_name": "Toll Free Number", 
            "phone": "1-888-577-8839"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of participants achieving Sustained Virologic Response 12 weeks after the end of all study therapy (SVR12)", 
                "safety_issue": "No", 
                "time_frame": "Up to 30 weeks"
            }, 
            {
                "measure": "Number of participants experiencing at least one Adverse Event (AE) on study", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 42 weeks"
            }, 
            {
                "measure": "Number of participants discontinuing study therapy due to an AE", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 18 weeks"
            }
        ], 
        "removed_countries": {
            "country": [
                "France", 
                "Denmark"
            ]
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01717326"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Time to first achievement of undetectable hepatitis C virus ribonucleic acid (HCV RNA)", 
                "safety_issue": "No", 
                "time_frame": "Up to 18 weeks"
            }, 
            {
                "measure": "Number of participants achieving undetectable HCV RNA at Week 2", 
                "safety_issue": "No", 
                "time_frame": "Week 2"
            }, 
            {
                "measure": "Number of participants achieving undetectable HCV RNA at Week 4", 
                "safety_issue": "No", 
                "time_frame": "Week 4"
            }, 
            {
                "measure": "Number of participants achieving undetectable HCV RNA at Week 12", 
                "safety_issue": "No", 
                "time_frame": "Week 12"
            }, 
            {
                "measure": "Number of participants achieving HCV RNA <25 IU/mL at Week 2", 
                "safety_issue": "No", 
                "time_frame": "Week 2"
            }, 
            {
                "measure": "Number of participants achieving HCV RNA <25 IU/mL at Week 4", 
                "safety_issue": "No", 
                "time_frame": "Week 4"
            }, 
            {
                "measure": "Number of participants achieving HCV RNA <25 IU/mL at Week 12", 
                "safety_issue": "No", 
                "time_frame": "Week 12"
            }, 
            {
                "measure": "Number of participants achieving End-Of-Treatment Response (EOTR)", 
                "safety_issue": "No", 
                "time_frame": "Up to 18 weeks"
            }, 
            {
                "measure": "Number of participants achieving Sustained Virologic Response 4 weeks after the end of all therapy (SVR4)", 
                "safety_issue": "No", 
                "time_frame": "Up to 22 weeks"
            }, 
            {
                "measure": "Number of participants achieving Sustained Virologic Response 24 weeks after the end of all study therapy (SVR24)", 
                "safety_issue": "No", 
                "time_frame": "Up to 42 weeks"
            }
        ], 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}